Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $87.9 million.

  • Pharming's Total Current Liabilities rose 1011.41% to $87.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.9 million, marking a year-over-year increase of 1011.41%. This contributed to the annual value of $73.8 million for FY2024, which is 534.32% down from last year.
  • According to the latest figures from Q3 2025, Pharming's Total Current Liabilities is $87.9 million, which was up 1011.41% from $87.9 million recorded in Q2 2025.
  • Over the past 5 years, Pharming's Total Current Liabilities peaked at $207.3 million during Q1 2024, and registered a low of $46694.0 during Q3 2022.
  • Moreover, its 5-year median value for Total Current Liabilities was $65.0 million (2023), whereas its average is $63.8 million.
  • In the last 5 years, Pharming's Total Current Liabilities plummeted by 9990.01% in 2022 and then soared by 14565320.17% in 2023.
  • Quarter analysis of 5 years shows Pharming's Total Current Liabilities stood at $47206.0 in 2021, then surged by 126362.82% to $59.7 million in 2022, then soared by 30.6% to $78.0 million in 2023, then dropped by 5.34% to $73.8 million in 2024, then rose by 19.12% to $87.9 million in 2025.
  • Its last three reported values are $87.9 million in Q3 2025, $87.9 million for Q2 2025, and $77.5 million during Q1 2025.